CDKN2A and central nervous system cancer: According to the 2021 WHO classification, all IDH mutated diffuse, astrocytic, grade 2 and 3 gliomas should be tested for CDKN2A/B homozygous deletion, since the presence of this marker would assign a grade 4 glioma [6, 7].